Loading...
XIDX
TSPC
Market cap738mUSD
Nov 12, Last price  
2,930.00IDR
Name

Tempo Scan Pacific Tbk PT

Chart & performance

D1W1MN
XIDX:TSPC chart
P/E
9.39
P/S
0.94
EPS
311.93
Div yield, %
2.56%
Shrs. gr., 5y
0.04%
Rev. gr., 5y
5.01%
Revenues
14.01t
+2.57%
2,729,223,518,3283,124,072,589,8113,633,789,178,6474,497,931,021,1135,134,242,102,1545,780,664,117,0376,630,809,553,3436,854,889,233,1217,512,115,037,5878,181,481,867,1799,138,238,993,8429,565,462,045,19910,088,118,830,78010,993,842,057,74710,968,402,090,24611,234,443,003,63912,254,369,318,12013,119,784,555,98713,654,570,830,00014,005,028,134,000
Net income
1.41t
-2.83%
272,583,806,584278,357,723,400320,647,898,367359,964,376,338488,889,258,921566,048,397,448627,950,145,504634,622,746,467579,379,534,765521,959,194,423536,273,826,937543,803,896,478512,028,758,825554,263,001,029787,803,135,441823,767,936,7911,001,627,721,8501,177,431,714,4781,447,724,541,0001,406,763,933,000
CFO
1.42t
-17.33%
234,892,877,849294,712,577,526292,296,080,215476,589,761,145578,089,303,003587,799,605,916635,028,604,390448,669,480,614501,514,626,600778,361,981,647491,655,348,447562,484,172,314441,132,846,384889,775,270,261982,698,939,026689,652,508,3301,193,325,533,5401,199,458,669,2781,714,658,233,0001,417,555,784,000
Dividend
Jun 17, 202650 IDR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

PT Tempo Scan Pacific Tbk, an Indonesian company headquartered in Jakarta with an international presence, operates primarily across three core business segments: pharmaceuticals, consumer products and cosmetics, and distribution services. Its activities encompass the trading of pharmaceutical and medical devices, alongside the manufacturing of diverse goods such as soaps, herbal products, powdered milk, food and beverages, and plastic packaging. The company also produces and markets a variety of consumer goods, cosmetic lines, and household items. Products are sold under an extensive portfolio of brands, including Bodrex, Oskadon, Neo rheumacyl, Bodrexin, Contrexyn, Contrex, Oskadryl, Neodulax, Vidoran, Hemaviton, Neo Hormoviton, Polaris, Vitonal, Vitamin IPI, Neo rheumacyl Herbal, Wybert Herbal, Bodrexin Herbal, Herbalax, Marina, Natural Honey, Claudia, MY BABY, MY BABY Kids, Pure Baby, S.O.S, Total Care, and ULTIMA II. Beyond these, PT Tempo Scan Pacific Tbk offers a range of supplementary services, including property construction and leasing, warehousing and freight forwarding, advertising and promotion, research and development, and information technology and communication network systems. It also manages procurement, distribution, and marketing functions. Established in 1970, the company was formerly known as PT Scanchemie and functions as a subsidiary of PT Bogamulia Nagadi.

Key people

Dian Paramita Tamzil
President Commissioner · since 1995
Phillips Gunawan
Director · since 2019
Rorita Lim
Director · since 2019
Linda Lukitasari
Director · since 2015
Dondi Sapto Margono
Director · since 1998
Liza Prasodjo
Director · since 2012
Hartaty Susanto
Director · since 2012
Prayoga Wahyudianto
Director · since 2016
I. Made Dharma Wijaya
Director · since 2018
Shania
Independent Director, Corporate Secretary · since 2017
Olga Asihjati Adjiputro Wijaya
Independent Commissioner · since 1997
IPO date
Jun 17, 1994
Employees
4,545
Domiciled in
ID
Incorporated in
ID

Valuation

Title
IDR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT